Targeted Pre-Launch Scientific Outreach Drives 40% Faster Treatment Adoption
Veeva Systems' latest Pulse Field Trends Report reveals that targeted pre-launch scientific outreach significantly accelerates treatment adoption. Key findings include:
1. Biopharmas investing in pre-launch scientific activities and prioritizing congresses achieve 40% faster treatment adoption.
2. Early-career experts are four times more likely to start patients on new treatments and more open to digital engagement.
3. Congress activity has the strongest influence on clinical decisions post-approval.
4. Engaging early-career HCPs increases new treatment uptake, with these experts being five times more likely to speak at congresses and 11 times more likely to engage digitally.
The report emphasizes the importance of expanding engagement strategies beyond traditional experts and investing in different types of scientific outreach to drive greater impact and faster treatment adoption.
Il più recente Pulse Field Trends Report di Veeva Systems rivela che l'outreach scientifico mirato pre-lancio accelera significativamente l'adozione dei trattamenti. I risultati chiave includono:
1. Le biopharma che investono in attività scientifiche pre-lancio e danno priorità ai congressi raggiungono un'adozione dei trattamenti che è il 40% più veloce.
2. Gli esperti all'inizio della carriera sono quattro volte più propensi a iniziare i pazienti con nuovi trattamenti e mostrano una maggiore apertura all'engagement digitale.
3. L'attività congressuale ha la maggiore influenza sulle decisioni cliniche dopo l'approvazione.
4. Coinvolgere gli operatori sanitari all'inizio della carriera aumenta l'adozione di nuovi trattamenti, con questi esperti che sono cinque volte più propensi a parlare ai congressi e 11 volte più propensi a impegnarsi digitalmente.
Il rapporto sottolinea l'importanza di espandere le strategie di coinvolgimento oltre agli esperti tradizionali e investire in diversi tipi di outreach scientifico per ottenere un maggiore impatto e una rapida adozione dei trattamenti.
El último Informe sobre Tendencias del Campo Pulse de Veeva Systems revela que la divulgación científica dirigida antes del lanzamiento acelera significativamente la adopción de tratamientos. Los hallazgos clave incluyen:
1. Las biofarmacéuticas que invierten en actividades científicas previas al lanzamiento y priorizan los congresos logran una adopción de tratamientos un 40% más rápida.
2. Los expertos en etapa temprana de carrera tienen cuatro veces más probabilidades de iniciar a los pacientes en nuevos tratamientos y son más abiertos a la participación digital.
3. La actividad en congresos tiene la mayor influencia en las decisiones clínicas después de la aprobación.
4. Involucrar a los profesionales de la salud en las primeras etapas de su carrera aumenta la adopción de nuevos tratamientos, siendo estos expertos cinco veces más propensos a hablar en congresos y 11 veces más propensos a participar digitalmente.
El informe enfatiza la importancia de ampliar las estrategias de compromiso más allá de los expertos tradicionales e invertir en diferentes tipos de divulgación científica para impulsar un mayor impacto y una adopción más rápida de los tratamientos.
Veeva Systems의 최신 Pulse Field Trends Report는 목표 지향적 사전 출시 과학홍보가 치료 채택을 더욱 빠르게 한다고 밝혔습니다. 주요 발견은 다음과 같습니다:
1. 사전 출시 과학 활동에 투자하고 학술 대회를 우선시하는 생명공학 기업은 치료 채택 속도가 40% 더 빠릅니다.
2. 경력이 짧은 전문가들은 환자에게 새로운 치료를 시작할 가능성이 네 배 더 높으며 디지털 참여에 더 개방적입니다.
3. 학술 대회 활동은 승인 후 임상 결정에 가장 큰 영향을 미칩니다.
4. 초기 경력의 의료 전문가들을 참여시키면 새로운 치료의 채택이 증가하며, 이들 전문가는 학술 대회에서 발표할 가능성이 다섯 배 더 높고 디지털로 참여할 가능성이 11배 더 높습니다.
이 보고서는 전통적인 전문가를 넘어 참여 전략을 확장하고 다양한 유형의 과학 홍보에 투자하는 것이 더 큰 영향을 미치고 치료 채택을 가속화하는 것이 중요하다고 강조합니다.
Le dernier rapport Pulse Field Trends de Veeva Systems révèle que la sensibilisation scientifique ciblée avant le lancement accélère considérablement l'adoption des traitements. Les principales conclusions incluent :
1. Les biopharmas qui investissent dans des activités scientifiques pré-lancement et qui priorisent les congrès réalisent une adoption des traitements 40% plus rapide.
2. Les experts de début de carrière sont quatre fois plus susceptibles de commencer des patients avec de nouveaux traitements et sont plus ouverts à l'engagement numérique.
3. L'activité lors des congrès a la plus forte influence sur les décisions cliniques après approbation.
4. Impliquer des professionnels de santé en début de carrière augmente l'adoption des nouveaux traitements, ces experts étant cinq fois plus susceptibles de parler lors de congrès et 11 fois plus susceptibles de s'engager numériquement.
Le rapport souligne l'importance d'élargir les stratégies d'engagement au-delà des experts traditionnels et d'investir dans différents types de sensibilisation scientifique pour générer un plus grand impact et une adoption plus rapide des traitements.
Der neueste Pulse Field Trends Report von Veeva Systems zeigt, dass gezielte wissenschaftliche Kommunikation vor dem Launch die Behandlungsaufnahme erheblich beschleunigt. Zu den wichtigsten Erkenntnissen gehören:
1. Biopharma-Unternehmen, die in wissenschaftliche Aktivitäten vor dem Launch investieren und Kongresse priorisieren, erreichen eine um 40% schnellere Behandlungsannahme.
2. Experten in der frühen Karriere sind viermal so wahrscheinlich, Patienten mit neuen Behandlungen zu beginnen und offener für digitale Interaktionen.
3. Kongressaktivitäten haben den stärksten Einfluss auf klinische Entscheidungen nach der Genehmigung.
4. Die Einbindung von medizinischen Fachkräften in der frühen Karriere erhöht die Annahme neuer Behandlungen, wobei diese Experten fünfmal wahrscheinlicher bei Kongressen sprechen und 11-mal wahrscheinlicher digital interagieren.
Der Bericht betont die Bedeutung, Engagement-Strategien über traditionelle Experten hinaus zu erweitern und in verschiedene Arten wissenschaftlicher Kommunikation zu investieren, um einen größeren Einfluss und eine schnellere Behandlungsaufnahme zu erzielen.
- Pre-launch scientific activities and congress prioritization lead to 40% faster treatment adoption
- Early-career experts are four times more likely to start patients on new treatments
- Congress activity has the strongest influence on clinical decisions post-approval
- Early-career HCPs are five times more likely to speak at congresses and 11 times more likely to engage digitally
- None.
Insights
The latest Veeva Pulse Field Trends Report offers intriguing insights into the pharmaceutical industry's pre-launch strategies and their impact on treatment adoption. As a market research analyst, I find several key points particularly noteworthy:
- Companies investing in targeted pre-launch scientific activities achieve
40% faster treatment adoption compared to those with lower investments. This significant difference underscores the importance of early engagement in the pharmaceutical market. - The focus on congresses as a primary influencer of clinical decisions is a game-changer. It suggests that companies should allocate more resources to these events to maximize their impact on treatment adoption post-approval.
- The emergence of early-career healthcare professionals (HCPs) as key influencers is reshaping the landscape of medical engagement. These HCPs are four times more likely to start patients on new treatments, indicating a more open attitude towards innovation.
From a market perspective, these findings suggest a shift in how pharmaceutical companies should approach their pre-launch strategies. The emphasis on digital engagement, particularly with early-career HCPs, aligns with broader trends in healthcare communication and information dissemination. Companies that adapt to these trends are likely to see improved market penetration and faster adoption of their treatments.
However, it's important to note that this strategy may require significant investment in medical affairs teams and digital infrastructure. The return on investment, while potentially substantial, may vary depending on the specific treatment and target market. Companies will need to carefully balance their resource allocation to maximize the benefits of this approach.
As a medical research analyst, I find the Veeva Pulse Field Trends Report's findings on the impact of pre-launch scientific activities particularly compelling. The report highlights several critical aspects that could significantly influence how medical affairs teams operate:
- The
40% faster treatment adoption rate for companies investing in targeted pre-launch activities is a clear indicator of the importance of early scientific engagement. This suggests that medical affairs teams should be more involved in the pre-launch phase, focusing on clinical guidelines, publications and congress activities. - The report's emphasis on congresses as the most influential factor in clinical decisions post-approval is noteworthy. It implies that medical affairs teams should prioritize participation and presentation at these events to maximize their impact on treatment adoption.
- The identification of early-career HCPs as key influencers in treatment adoption is a significant finding. Their higher likelihood of starting patients on new treatments (4 times more likely) and their increased engagement in digital platforms, congresses and publications suggest that medical affairs teams should develop strategies specifically targeting this group.
From a medical research perspective, these findings underscore the evolving role of medical affairs in the pharmaceutical industry. The traditional focus on top-tier scientific thought leaders is shifting towards a broader, more diverse group of stakeholders. This change requires a more nuanced approach to scientific communication and engagement.
However, it's important to note that while faster treatment adoption is generally positive, it must be balanced with thorough safety and efficacy considerations. Medical affairs teams should ensure that their pre-launch activities provide comprehensive, unbiased information to support informed clinical decision-making.
New Veeva Pulse findings show congresses and early-career experts have the strongest influence on patient outcomes
Healthcare professionals (HCPs) are turning to biopharmas to help distill rapidly evolving scientific evidence around new innovative medicines and complex diseases. By focusing pre-launch activity around clinical guidelines, publications, and congresses with a new group of stakeholders, medical affairs teams can reach key HCPs to improve treatment decisions.
"Gone are the days when medical could just focus on the top-tier scientific thought leaders," said Angela Smart, director of global medical excellence and operations at ADVANZ PHARMA. "The range of stakeholders has broadened, and it's imperative to expand our engagement strategies beyond traditional experts."
The latest analysis from Veeva Pulse finds that:
- Targeted pre-launch scientific activities speed treatment adoption: By engaging key experts at congresses, helping develop clinical guidelines, and securing coverage in publications before launch, companies see
40% faster treatment adoption than those that invest less in this outreach. This demonstrates that more resources for medical teams during this stage can boost launch success. - Congress activity has the strongest influence on clinical decisions: Higher investment in pre-launch congress activities has the most influence on treatment after approval. Congresses, and the digital discussions that follow, help increase scientific awareness and drive impactful medical conversations more than investment in clinical guidelines and publications.
- Engaging early-career HCPs increases new treatment uptake: These digitally-savvy emerging experts are four times more likely to start patients on a new treatment. They are also five times more likely to speak at congresses, 11 times more likely to engage digitally, and seven times more likely to get published.
"As HCPs gain an increasing amount of information to understand complex new medicines across channels, effectively communicating scientific evidence before launch can make all the difference," said Dan Rizzo, vice president of business consulting at Veeva. "By investing in different types of scientific outreach and engaging newer experts during this crucial window, medical teams can drive greater impact and faster treatment adoption."
About the Veeva Pulse Field Trends Report
Analyzing over 600 million HCP interactions and activities annually from more than
Additional Information
To download a copy of the Veeva Pulse Field Trends Report, visit: veeva.com/FieldTrends
Learn more about Veeva Business Consulting: veeva.com/BusinessConsulting
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 35 and 36), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Alison Borris
Veeva Systems
925-226-8821
alison.borris@veeva.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/targeted-pre-launch-scientific-outreach-drives-40-faster-treatment-adoption-302206400.html
SOURCE Veeva Systems
FAQ
What is the impact of targeted pre-launch scientific outreach on treatment adoption according to Veeva Systems (VEEV)?
How do early-career experts influence new treatment uptake as per Veeva Systems' (VEEV) report?
What type of pre-launch activity has the strongest influence on clinical decisions according to Veeva Systems (VEEV)?
How does Veeva Systems (VEEV) suggest medical teams can drive greater impact and faster treatment adoption?
